Warfarin-related outcomes in patients with antiphospholipid antibody syndrome managed in an anticoagulation clinic

Summary

Patients with antiphospholipid antibody syndrome (APA) are at elevated risk of venous and arterial thromboembolic complications. Oral anticoagulation with warfarin is recommended for secondary prevention of thromboembolism, but warfarin-related outcomes have not been systematically investigated when warfarin therapy is managed by a dedicated anticoagulation clinic.The objectives of the study were to evaluate warfarin-related monitoring outcomes, clinical endpoints and the use of healthcare resources as a result of warfarin-related complications in patients with APA compared to a group of patients without APA, all of whom were managed in an anticoagulation clinic setting. A retrospective observational cohort design was used to investigate patients with and without APA, all of whom had a history of venous or arterial thromboembolism, and were matched for age, gender and indication for oral anticoagulation. Thirty-six APA patients taking warfarin were compared to a matched cohort of 36 patients without APA. Monitoring outcomes (time in therapeutic range, clinic visits per year, frequency of warfarin dosing adjustments, reasons for out-of-range INRs) were similar between groups, as was the frequency of major bleeding complications (3.2%/pt-yr vs. 3.1%/pt-yr). However, recurrent thromboembolic events (9.6%/pt-yr vs 0) occurred more frequently in APA patients. APA patients required more emergency room visits (6.4%/pt-yr vs. 1.6%/pt-yr) and hospital admissions (14.4%/pt-yr vs.3.0%/pt-yr) to manage complications of warfarin therapy. In conclusion, despite similar monitoring outcomes obtained in a dedicated anticoagulation clinic setting, adverse clinical outcomes are significantly more frequent in patients with APA syndrome than in those without APA, and require more frequent use of healthcare resources.

Keywords

Warfarin - antiphospholipid antibody syndrome - thrombosis - anticoagulation clinic

• References

• 1 Levine JS, Branch R, Rauch J. The antiphospholipid syndrome. New EnglJ Med 2002; 346: 752-63.
• 2 Cervera R, Piette JC, Font J. et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression ina cohort of 1,000 patients. Arthritis Rheum 2002; 46: 1019-27.
• 3 Albers GW, Amarenco J, Easton JD. et al. Antithrombotic and thrombolytic therapy for ischemic stroke: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 483s-512s.
• 4 Büller HR, Agnelli G, Hull RD. et al. Antithrombotic therapy for venous thromboembolic disease: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 401s-428s.
• 5 Krnic-Barrie S, O’Connor CR, Looney SW. et al. A retrospective review of 61 patients with antiphospholipid syndrome: analysis of factors influencing recurrent thrombosis. Arch Intern Med 1997; 157: 2101-8.
• 6 Rosove MH, Brewer PM. Antiphospholipid thrombosis: clinical course after the first thromboembolic event in 70 patients. Ann Intern Med 1992; 117: 303-8.
• 7 Ruiz-Irastorza G, Shamashta MA, Hunt BJ. et al. Bleeding and recurrent thrombosis in definite antiphospholipid syndrome Analysis of a series of 66 patients treated with oral anticoagulation toa target International Normalized Ratio of 3.5. Arch Intern Med 2002; 162: 1164-9.
• 8 Khamashta MA, Cuadrado MJ, Mujic F. et al. The management of thrombosis in the antiphospholipid antibody syndrome. N Engl J Med 1995; 332: 993-7.
• 9 Ansell J. Optimizing the efficacy and safety of oral anticoagulant therapy: high-quality dose management, anticoagulation clinics, and patient self-management. Semin Vasc Med 2003; 03: 261-70.
• 10 Chiquette E, Amato M, Bussey H. Comparison of an anticoagulation clinic with usual medical care: anticoagulation control, patient outcomes, and health care costs. Arch Intern Med 1998; 158: 1641-7.
• 11 Witt DM, Sadler MA, Shanahan RL. et al. Effect of a centralized clinical pharmacy anticoagulation service on the outcomes of anticoagulation therapy. Chest 2005; 127: 1515-22.
• 12 Wittkowsky AK, Devine EB. Frequency and causes of overanticoagulation and underanticoagulation in patients treated with warfarin. Pharmacotherapy 2004; 24: 1311-6.
• 13 Crowther MA, Ginsberg JS, Julian J. et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 2003; 349: 1133-8.
• 14 Finazzi G, Marchioli R, Brancaccio V. et al. A randomized clinical trial of high-intensity warfarin versus conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome (WAPS). J Thromb Haemost 2005; 03: 848-53.
• 15 Moll S, Oertel TL. Monitoring warfarin therapy in patients with lupus anticoagulants. Ann Intern Med 1997; 127: 177-85.
• 16 Rosborough TK, Shepard MF. Unreliability of international normalized ratio for monitoring warfarin therapy in patients with lupus anticoagulant. Pharmacotherapy 2004; 24: 838-42.
• 17 Dentali F, Manfredi E, Crowther M. et al. Long-duration therapy with low molecular weight heparin in patients with antiphospholipid antibody syndrome resistant to warfarin therapy. J Thromb Haemost 2005; 03: 2121-3.
• 18 Rouby RAS. New approaches to prevention of thrombosis in the antiphospholipid syndrome: hopes, trials, and tribulations. Arthritis Rheum 2003; 48: 3004-8.